These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36238195)

  • 1. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.
    Tavakoli GM; Yazdanpanah N; Rezaei N
    Adv Rheumatol; 2024 Aug; 64(1):61. PubMed ID: 39169436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D; Geladaris A; Dybowski S; Weber MS
    Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
    García-Merino A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
    Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
    Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
    Torke S; Weber MS
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
    Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
    J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the Role of the Glycogen Synthase Kinase-3β, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis.
    Mohite R; Gharat S; Doshi G
    Endocr Metab Immune Disord Drug Targets; 2024; 24(10):1131-1145. PubMed ID: 38284723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.